This Fc-enhanced anti-CD40 agonist antibody (2141-V11) was used for treatment in orthotopic murine bladder cancer models and achieved greater anti-tumor capabilities than both controls and BCG therapy through enhanced CD8+ T cell-dependent response. Here, CD8A is linked to urinary bladder cancer.